Beyond EGFR mutations, MET amplification also mediates resistance to TKIs targeting ALK, ROS1, and RET fusions, and the KRAS G12C mutation in lung cancer [27] Bevacizumab may help overcome MET‐mediated resistance by targeting the hepatocyte growth factor‐driven VEGF production and subsequent angiogenesis that supports tumor growth and therapeutic resistance [28]. This evidence concerns the gene ALK and lung carcinoma.